Chembio Diagnostics Profit Margin 2006-2018 | CEMI
Current and historical gross margin, operating margin and net profit margin for Chembio Diagnostics (CEMI) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Chembio Diagnostics net profit margin as of December 31, 2018 is -23.54%.
| Chembio Diagnostics Annual Profit Margins |
|---|
| Chembio Diagnostics Quarterly Profit Margins |
|---|
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $0.097B | $0.033B |
| CHEMBIO DIAGNOSTICS, INC. develops, manufactures, licenses and markets proprietary rapid diagnostic tests in the growing $5 billion point-of-care testing market. Chembio's two FDA PMA-approved, CLIA-waived, rapid HIV tests are marketed in the U.S. by a third party company. Chembio markets its HIV STAT-PAK line of rapid HIV tests internationally to government and donor-funded programs directly and through distributors. Chembio also has rapid tests for veterinary tuberculosis and chagas disease. In 2007 Chembio received a U.S. patent for its Dual Path Platform technology which has significant advantages over lateral-flow technologies. This technology is providing Chembio with a significant pipeline of business opportunities for the development and manufacture of new products based on DPP. Chembio is licensed by the U.S. Food and Drug Administration as well as the U. S. Department of Agriculture, and is certified for the global market under the International Standards Organization directive 13.485. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $140.623B | 27.80 |
| Medtronic (MDT) | Ireland | $123.520B | 18.06 |
| Stryker (SYK) | United States | $73.875B | 27.09 |
| Boston Scientific (BSX) | United States | $52.874B | 25.78 |
| Baxter (BAX) | United States | $40.209B | 25.72 |
| Zimmer Biomet Holdings (ZBH) | United States | $26.486B | 16.96 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $17.634B | 0.00 |
| Canopy Growth (CGC) | Canada | $15.407B | 0.00 |
| ResMed (RMD) | United States | $14.469B | 27.44 |
| Aurora Cannabis (ACB) | Canada | $9.687B | 68.36 |
| Bio-Rad Laboratories (BIO) | United States | $9.455B | 53.94 |
| Hill-Rom Holdings (HRC) | United States | $7.140B | 22.08 |
| Perrigo (PRGO) | Ireland | $6.601B | 10.70 |
| Insulet (PODD) | United States | $6.039B | 2037.40 |
| GW Pharmaceuticals (GWPH) | United Kingdom | $5.309B | 0.00 |
| ICU Medical (ICUI) | United States | $4.841B | 30.14 |
| Haemonetics (HAE) | United States | $4.496B | 39.88 |
| Hutchison China MediTech (HCM) | China | $3.961B | 0.00 |
| Agios Pharmaceuticals (AGIO) | United States | $3.830B | 0.00 |
| Neogen (NEOG) | United States | $3.332B | 51.18 |
| NuVasive (NUVA) | United States | $2.927B | 25.53 |
| Quidel (QDEL) | United States | $2.672B | 24.11 |
| Aphria (APHA) | $2.518B | 111.78 | |
| National Vision Holdings (EYE) | United States | $2.327B | 45.77 |
| HEXO (HEXO) | $1.429B | 0.00 | |
| Cardiovascular Systems (CSII) | United States | $1.402B | 1006.25 |
| Phibro Animal Health (PAHC) | United States | $1.308B | 18.80 |
| VAREX IMAGING (VREX) | United States | $1.299B | 25.44 |
| AtriCure (ATRC) | United States | $1.104B | 0.00 |
| Lantheus Holdings (LNTH) | United States | $0.968B | 26.15 |
| MacroGenics (MGNX) | United States | $0.967B | 0.00 |
| Cerus (CERS) | United States | $0.885B | 0.00 |
| PetIQ (PETQ) | United States | $0.872B | 24.96 |
| Omeros (OMER) | United States | $0.868B | 0.00 |
| NanoString Technologies (NSTG) | United States | $0.753B | 0.00 |
| Meridian Bioscience (VIVO) | United States | $0.727B | 21.67 |
| OraSure Technologies (OSUR) | United States | $0.713B | 31.24 |
| Eagle Pharmaceuticals (EGRX) | United States | $0.705B | 23.99 |
| Evolus (EOLS) | United States | $0.701B | 0.00 |
| TG Therapeutics (TGTX) | United States | $0.650B | 0.00 |
| Surmodics (SRDX) | United States | $0.618B | 89.94 |
| LeMaitre Vascular (LMAT) | United States | $0.614B | 29.21 |
| Quanterix (QTRX) | United States | $0.551B | 0.00 |
| BioLife Solutions (BLFS) | United States | $0.397B | 163.54 |
| Vapotherm (VAPO) | United States | $0.371B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.363B | 0.00 |
| Insys Therapeutics (INSY) | United States | $0.358B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.312B | 20.30 |
| Owens & Minor (OMI) | United States | $0.284B | 3.94 |
| Bovie Medical (APYX) | United States | $0.264B | 0.00 |
| Neptune Technologies & Bioresources Inc (NEPT) | Canada | $0.257B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.255B | 0.00 |
| Zynex (ZYXI) | United States | $0.143B | 15.35 |
| Fonar (FONR) | United States | $0.143B | 7.64 |
| Surface Oncology (SURF) | United States | $0.117B | 0.00 |
| Chimerix (CMRX) | United States | $0.102B | 0.00 |
| Female Health (VERU) | United States | $0.100B | 0.00 |
| InfuSystems Holdings (INFU) | United States | $0.090B | 0.00 |
| Conatus Pharmaceuticals (CNAT) | United States | $0.088B | 0.00 |
| United-Guardian (UG) | United States | $0.087B | 20.01 |
| CAS Medical Systems (CASM) | United States | $0.071B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.071B | 21.00 |
| Neurotrope (NTRP) | United States | $0.061B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.056B | 0.00 |
| ImmuCell (ICCC) | United States | $0.038B | 0.00 |
| Valeritas Holdings (VLRX) | United States | $0.036B | 0.00 |
| Senestech (SNES) | United States | $0.028B | 0.00 |
| Myomo (MYO) | United States | $0.022B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.018B | 0.00 |
| InVivo Therapeutics Holdings (NVIV) | United States | $0.015B | 0.00 |
| Akers Biosciences Inc (AKER) | United States | $0.014B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.012B | 0.00 |
| NeuroMetrix (NURO) | United States | $0.009B | 15.57 |
